1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,954 | 1,006 | 11:36 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:00 | XSpray Pharma AB: Xspray Pharma provides regulatory status update for Dasynoc and Nilopki | 72 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today provides an update on the regulatory status for its two lead product candidates, Dasynoc and Nilopki. The Company reiterates its plan to resubmit the New Drug Applications... ► Artikel lesen | |
| 20.08. | Xspray's Dasynoc approval bid foiled again by FDA's manufacturer concerns | 3 | FiercePharma | ||
| 19.08. | XSpray Pharma AB: Xspray Pharma receives Complete Response Letter (CRL) from FDA for Dasynoc | 951 | GlobeNewswire (Europe) | The FDA's Complete Response Letter relates to the previously communicated observations at NerPharMa, concerning outstanding GMP (Good Manufacturing Practice) observations, as well as a request for additional... ► Artikel lesen | |
| 05.08. | XSpray Pharma AB: Xspray Pharma Interim Report Second Quarter 2026 | 502 | GlobeNewswire (Europe) | April-June 2026, Group Net sales amounted to SEK 0 thousand (0) Earnings before tax amounted to SEK -39,794 thousand (-44,885) Earnings per share before dilution amounted to SEK -0.87 (-1.21) Cash flow... ► Artikel lesen | |
| XSPRAY PHARMA Aktie jetzt für 0€ handeln | |||||
| 26.06. | XSpray Pharma AB: Xspray Pharma provides regulatory update on its US product candidates Nilopki and Dasynoc and notes continued progress with its third-party manufacturer NerPharMa | 627 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) provides an update on the FDA review of its two US new drug applications. For Nilopki®, Xspray has defined an approach to address the items raised... ► Artikel lesen | |
| 05.06. | XSpray Pharma AB: Xspray Pharma Receives CRL from U.S. FDA for Nilopki | 361 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap technology platform to develop improved versions of marketed protein kinase inhibitors (PKIs)... ► Artikel lesen | |
| 03.06. | XSpray Pharma AB: Xspray Pharma employees fully participate in market priced long term incentive programs, signaling strong confidence ahead | 248 | GlobeNewswire (Europe) | Xspray Pharma's two newly implemented long-term incentive programs, LTIP 2025/2028 and LTIP 2026/2029, have reached full participation from the employees to whom they were offered. Participating employees... ► Artikel lesen | |
| 12.05. | XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026 | 225 | GlobeNewswire (Europe) | The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 12 May 2026.Adoption of income statement and balance sheet for the financial... ► Artikel lesen | |
| 28.04. | XSpray Pharma AB: Interim Report First Quarter 2026 | 338 | GlobeNewswire (Europe) | January-March 2026, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -35,380 thousand (-42,321)Earnings per share before dilution amounted to SEK -0.85 (-1.14)Cash flow... ► Artikel lesen | |
| 23.04. | XSpray Pharma AB: Xspray's rights issue oversubscribed - over-allotment issue fully utilized | 293 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 14.04. | XSpray Pharma AB: FDA accepts trade name Nilopki for Xspray's drug candidate XS003 (nilotinib) | 840 | GlobeNewswire (Europe) | The US Food and Drug Administration (FDA) has accepted Nilopki® as the proprietary name for Xspray Pharma's drug candidate XS003 (nilotinib). Nilopki is an improved, amorphous formulation of nilotinib... ► Artikel lesen | |
| 31.03. | XSpray Pharma AB: Xspray publishes disclosure document regarding rights issue | 233 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 31.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.03.2026 | 405 | Xetra Newsboard | Das Instrument OJ3 SE0009779796 SEAFIRE CAPITAL SK 10 EQUITY wird ex Kapitalmassnahme gehandelt am 31.03.2026 The instrument OJ3 SE0009779796 SEAFIRE CAPITAL SK 10 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 26.03. | XSpray Pharma AB: Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased | 288 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 24.03. | XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue | 383 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 11.03. | XSpray Pharma AB: Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc - PDUFA date August 25, 2026 | 605 | GlobeNewswire (Europe) | The U.S. Food and Drug Administration (FDA) has accepted Xspray Pharma's resubmitted New Drug Application (NDA) for Dasynoc® for review under the 505(b)(2) procedure. The FDA has set a PDUFA date of... ► Artikel lesen | |
| 26.02. | XSpray Pharma AB: Xspray Pharma re-submits its FDA application for Dasynoc | 398 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc® to the U.S. Food and Drug Administration (FDA). Dasynoc® is the company's lead product candidate - an amorphous... ► Artikel lesen | |
| 26.02. | XSpray Pharma AB: Xspray Pharma appoints Blake Leitch as CEO - Per Andersson continues as Chief Scientific Officer (CSO) | 363 | GlobeNewswire (Europe) | The Board of Directors of Xspray Pharma has today appointed Blake Leitch as CEO of Xspray Pharma, effective no later than June 1, 2026. He brings over 20 years of international experience of marketing... ► Artikel lesen | |
| 12.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2025 | 218 | GlobeNewswire (Europe) | October-December 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -37,009 thousand (-82,002)Earnings per share before dilution amounted to SEK -0.89 (-2.36)Cash... ► Artikel lesen | |
| 05.11.25 | XSpray Pharma AB: Interim Report Third Quarter 2025 | 370 | GlobeNewswire (Europe) | July-September 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -47,332 thousand (-82,272)Earnings per share before dilution amounted to SEK -1.25 (-2.44)Cash flow... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,952 | -2,51 % | BERENBERG stuft Evotec auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Evotec nach einem Gespräch mit dem Konzernchef Christian Wojczewski mit einem Kursziel von 3,60 Euro auf "Hold" belassen.... ► Artikel lesen | |
| BB BIOTECH | 54,00 | -0,74 % | BB Biotech: KI verändert das Wie, nicht das Was | BB Biotech verbindet seit mehr als 30 Jahren wissenschaftliche Expertise mit einem konsequenten Investmentansatz im Biotechnologiesektor. Mit künstlicher Intelligenz entwickelt das Unternehmen diesen... ► Artikel lesen | |
| MODERNA | 170,78 | +1,57 % | Durchbrüche gegen Hautkrebs: Neue Ansätze von Biofrontera und Moderna - Vidac Pharma vor heißem Herbst | Die Behandlung von Hautkrebs und dessen Vorstufen glich lange einem handwerklichen Kompromiss: Mediziner griffen zum Skalpell, froren betroffene Stellen ein oder verordneten aggressive Cremes, die das... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,550 | +0,41 % | Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors. | ||
| NANOREPRO | 1,605 | +0,31 % | EQS-News: NanoRepro AG: Deutsche Kosmetikwerke AG wird Tochterunternehmen - Aktientausch sichert NanoRepro die Stimmrechtsmehrheit - Plattform-Struktur nimmt weiter Form an | EQS-News: NanoRepro AG
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung/Strategische Unternehmensentscheidung
NanoRepro AG: Deutsche Kosmetikwerke AG wird Tochterunternehmen... ► Artikel lesen | |
| AAP IMPLANTATE | 1,650 | -4,07 % | aap Implantate: Cornelius Fink und Nicole Kassel neu im Vorstand | Bei aap Implantate kommt es zu Veränderungen im Vorstand. CEO Rubino Di Girolamo wird sein Amt zum 31. Dezember 2026 im Einvernehmen mit dem Aufsichtsrat niederlegen und vorzeitig aus dem Vorstand ausscheiden.... ► Artikel lesen | |
| INFLARX | 1,521 | -0,33 % | InflaRx N.V.: InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development | Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced... ► Artikel lesen | |
| TEMPUS AI | 68,76 | +1,04 % | Tempus AI, Inc.: Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026 | Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in... ► Artikel lesen | |
| EDITAS MEDICINE | 2,210 | -1,78 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 51,90 | -0,23 % | The Strategic Financial Case for BioMarin Pharmaceutical (BMRN) | ||
| CARDIOL THERAPEUTICS | 1,334 | 0,00 % | Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early | ||
| EVONEXT | 2,360 | +8,26 % | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA publishes half-year report 2026 | EvoNext Holdings SA / Key word(s): Half Year Results
EvoNext Holdings SA publishes half-year report 2026
30-Sep-2026 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art.... ► Artikel lesen | |
| IDORSIA | 4,878 | -0,04 % | Jean-Paul Clozel, VR-Präsident und CEO ad interim Idorsia, im Interview | von Robert Jakob Moneycab.com: Herr Clozel, der mit Pharmakon abgeschlossener Darlehensvertrag über eine Viertelmilliarde Franken befreit Idorsia vom unmittelbaren Liquiditätsdruck. War das jetzt der... ► Artikel lesen | |
| MYRIAD GENETICS | 3,563 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen | |
| ALDEYRA | 1,100 | -5,17 % | H.C. Wainwright bestätigt Aldeyra-Aktie mit "Neutral" und Kursziel von 2 US-Dollar |
Das Unternehmen XSPRAY PHARMA AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,34 % bei einem Aktienkurs von 0,885 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XSPRAY PHARMA AB finden Sie auf Wallstreet Online.